( )2017 57 1 JournalofNanchangUniversity(MedicalSciences)2017Vol.57No.1 35 1 2a 2b (1. 510120; 2. a. ;b. 330006) : B7-H4 Elivision 30 15 30 20 CA125 96.7% (29/ 30) 53.3%(8/15) 30.0%(9/30) 5.0%(1/20) (P=0.000<0.05);B7-H4 (P>0.05) (P<0.05) ; : ; ; ; : R737.33 : A : 2095-4727 (2017)01-0035-05 DOI:10.13764/j.cnki.ncdm.2017.01.009 ExpressionandSignificanceofB7-H4inEndometrioid OvarianAdenocarcinoma WULan 1 YUXiao-hong 2a WU Hai-gen 2b (1.Departmentof Oncologic GynecologySun Yat-sen Memorial Hospital Zhongshan UniversityGuangzhou510120China;2a.Departmentof Pathology 2b.Departmentof Oncologic GynecologyJiangxi Maternaland Child Health HospitalNanchang330006China) ABSTRACT:Objective ToexploretheexpressionandclinicopathologicsignificanceofB7-H4in endometrioidovarianadenocarcinoma.methods TheexpressionofB7-H4 wasdeterminedbyu- singimmunohistochemicalelivisionmethodin30casesofendometrioidovarianadenocarcinoma 15casesofborderlineendometrioidtumoroftheovarian30casesofovarianendometriosisand20 normalovariantissues.therelationshipsofb7-h4expressiontoclinicopathologicfeaturesand preoperativeserum CA125levelswereanalyzed.Results ThepositiveexpressionratesofB7-H4 inendometrioidovarianadenocarcinomaborderlineendometrioidtumorovarianendometriosis andnormalovariantissueswere96.7%(29/30)53.3%(8/15)30.0%(9/30)and5.0%(1/20) respectively.diferencesweresignificantbetweenendometrioidovarianadenocarcinomaandother ovariantissues(p<0.05).theexpressionofb7-h4proteinwasnotassociatedwiththeageofpa- :2015-10-22 : (1988 ) : E-mial:wlwhg163@163.com
36 tientswithendometrioidovarianadenocarcinoma(p>0.05)butwascorrelatedwiththeclinical stageandpathologicalgrade(p<0.05).furthermorethere wasapositivecorrelationbetween tiveresidualfociwasrelatedtothehighexpressionofb7-h4.conclusion B7-H4isdifuselyand B7-H4expressionandpreoperativeserum CA125levels.Moreovertheoccurrenceofpostopera- highlyexpressedinendometrioidovarianadenocarcinomaandtheexpressionofb7-h4isassoci- atedwiththestageandgradeofthetumorsuggestingthatb7-h4playanimportantroleinthe occurrenceanddevelopmentofendometrioidovarianadenocarcinoma.inadditionb7-h4protein expressionispositivelycorrelatedwiththepreoperativeserum CA125levels.Thereforethedetec- tionofb7-h4proteinisconducivetotheearlydiagnosisofearlydiagnosis. KEY WORDS:endometrioidovarianadenocarcinoma;B7-H4 protein;immunohistochemistry; earlydiagnosis ( )2017 2 57 1 T 24(6.4~273.3)U ml -1 T TCR 3 CA125>65U ml -1 B7-H4 39 (21~45 ) B7-H4 T 18(5.4~128.6)U ml -1 2 CA125> 65U ml -1 T B7-H4 1.2 [1] ( 4μm) [2] [3] [4] [5] Elivision [6] B7-H4 PBS ( 1 350 :ab10836 Santacruz ) ( ) ( ) Elivision B7-H4 B7-H4 B7-H4 : =0 0 <10% 1 10% ~50% 2 50% ~80% 3 >80% 4 ; : 1 <10% 10%~100% 1.1 1.3 2007 1 3~5mL 2010 12 CA125 35 U ml -1 CA125=65 U ml -1 CA125>65 U 30 15 ml -1 30 1.4 20 49 (29~64 )FIGO(2009 ) :Ⅰ 15 Ⅱ 5 Ⅲ 10 Ⅰ 5 Ⅱ 1 3 1 13 Ⅲ 12 27 ( <2cm) 180(6.5~2540.0)U ml -1 18 CA125> 1.5 SPSS17.0 χ2 65U ml -1 Fisher Kruskua-WalisTest 43 (24~57 ) :Ⅰ 9 Ⅱ 4 Ⅲ B7-H4 2 Ⅰ 4 Ⅱ 7 Ⅲ 4 14 ( <2cm) CA125
: 37 P<0.05 ( ) 2 ( 1) 2.1 B7-H4 96.7% (29/30) 53.3% (8/15) 30.0% (9/30) 5.0%(1/20) (P=0.000<0.05) 1 2 A B C D A: ( );B: ( );C: ( );D: ( ) 1 1 B7-H4 B7-H4 / n % χ 2 P 0-1 2 3 4 χ 2 P 30 29 96.7 57.941 0.000 1 9 9 11-5.284 0.000 * 15 8 53.3 7 6 2 0-5.760 0.000 # 30 9 30.0 21 9 0 0-5.596 0.000 20 1 5.0 19 1 0 0 * ;# ; B7-H4 /% 100 80 60 40 20 0 1 2 3 4 B7-H4 2 2.2 B7-H4 39 (21~54 ) 2 (1 Ⅲc G2 B7-H4 41 3 1 ⅢB G2 23 4 ) 1 B7-H4 B7-H4 (Ⅲc G2 12 4 ) FIGO 1 (Ⅲc G2 19 2 ) FIGO B7-H4 (P<0.05) 2
38 ( )2017 2 57 1 2 B7-H4 n / (3~4 ) % χ 2 P n (3~4 ) % 45 13 9 69.2 0.068 0.794 8 4 50.0 0.077 0.782 >45 17 11 64.7 7 4 57.1 FIGO Ⅰ Ⅱ 20 10 50.0 7.5 0.006 13 6 46.1 2.019 0.155 Ⅲ 10 10 100.0 2 2 100.0 Ⅰ 24 14 58.0 3.75 0.053 12 5 41.2 3.281 0.07 Ⅱ Ⅲ 6 6 100.0 3 3 100.0 Ⅰ Ⅱ 18 9 50.0 5.625 0.018 11 5 45.4 1.029 0.31 Ⅲ 12 11 91.7 4 3 75.0 χ 2 P 2.3 B7-H4 Ⅰ Ⅱ 93.3% 100.0%B7-H4 CA125 65U ml -1 CA125 73% B7-H4 CA125 ( 0.655P<0.05) (P=0.000) B7-H4 97% Ⅰ Ⅱ 46.7% 60.0%CA125 3 3 3 35U ml -1 65U ml -1 >65U ml -1 % % % 8 27 3 10 19 63 29.203 0.000 11 73 1 7 3 20 25 83 3 10 2 7 χ 2 P B7-H4 /% 100 80 60 40 20 0 1 2 CA125 3 3 3 3.1 B7-H4 [10] B7-H4 [10] B7-H4 B7-H4 B7-H4 [7-8] Anderson
: 39 96.7% (29/30) 53.3% (8/15) 30.0%(9/30) 5.0%(1/20)CA125 52% 65% [17] Tringler Ⅱ Ⅲ Ⅲ [5] Simon Ⅰ Ⅰ B7-H4 Ⅱ B7-H4 B7-H4 CA125 B7-H4 ( ) : SCID [11-12] B7-H4 CD3+ CD8+T T Miyatake [13] CD3+ CD8+T Lu [14] CD3+ CD8+T B7-H4 B7-H4 IL-2 IL-10 IFN-r CD8+T 10B7-H4 CSF IL-4 Kryczek [10] IL-6 IL- B7- H4 B7-H4 B7-H4 T 3.2 B7-H4 CA125 90% ~ 94% 50% [15] CA125 Ⅰ 46.7% Ⅰ 93.3% [510] Simon [17] 2005306:128-141. CA125 [12]. B7-H4 CTL CA125 (4):253-256. H4 CA125 97% B7- [1] SunYWangYZhaoJetal.B7-H3andB7-H4expressionin non-smal-cellungcancer[j].lungcancer200653(2):143-151. [2] ChenLJSunJWu H Yetal.B7-H4expressionassociates withcancerprogressionandpredictspatient ssurvivalinhu- manesophagealsquamouscelcarcinoma[j].cancerimmunol Immunother201160(7):1047-1055. [3] ZhangJZhang MJiang Wetal.B7-H4genepolymorphisms areassociated withsporadicbreastcancerinachinese Han population[j].bmccancer20099:394. [4]. [J]. 201232(3): 177-181. [5] TringlerBLiu WCorralLetal.B7-H4overexpressionino- variantumors[j].gynecoloncol2006100(1):44-52. [6] Qian YShenLChengLetal.B7-H4expressioninvarious tumorsdeterminedusinganoveldeveloped monoclonalanti- body[j].clinexp Med201111(3):163-170. [7] ZangXThompsonR HAlAhmadie H Aetal.B7-H3and B7xarehighlyexpressedinhumanprostatecancerandassoci- atedwithdiseasespreadandpooroutcome[j].procnatlacad SciUSA2007104(49):19458-19463. [8] KrambeckA EThompsonR HDongHetal.B7-H4expres- sioninrenalcelcarcinomaandtumorvasculature:associations withcancerprogressionandsurvival[j].procnatlacadsci USA2006103(27):10391-10396. [9] AndersonG LMcIntosh MWuLetal.Assessingleadtime ofselected ovariancancerbiomarkers:anestedcase-control study[j].jnatlcancerinst2010102(1):26-38. [10] KryczekIZouLRodriguezPetal.B7-H4expressionidenti- fiesanovelsuppressivemacrophagepopulationinhumano- variancarcinoma[j].jexp Med2006203(4):871-881. [11] SalcedaSTang TKmet Metal.Theimmunomodulatory proteinb7-h4isoverexpressedinbreastandovariancancers andpromotesepithelialceltransformation[j].expcelres B7-H4 [J]. 200918 ( 49 )
: - BNP CVVH CVVH [17-19] CVVH HP CVVH AOPP : [1] ChowdharySBhatacharyyaRBanerjeeD.Acuteorganophospho- ruspoisoning[j].clinchim Acta2014431:66-76. (14):2785-2786. [2]. - [15]. [J]. 201232(24):5568-5569. 201334(2):290-292. [3]. [16]. [J]. - 201218(9):1200-1202. [J]. 201221(1):65-69. [4]. [17]. [J]. 201544(15):2114-2116. 201617(2):137-138. [5]. [M].12. : [18]. 2005:800-802. [J]. 2013 [6]. [M].2. : 2010:1226-1230. [7]. - [J]. 201538(7): 42 [J]. : 2012 482-485. 38(3):500. [J]. 201625(4): 495-498. [9]. - [8]. [J]. 201419(1):39-4050. [10]. - [12]. [J]. 201522 (16):40-41. [13].HP CVVH AST ctni AMS [J]. 201353(36):51-52. [14]. - [J]. 201131 [J]. : [J]. 47(4):367-369. [19]. ( : ) 櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐櫐 ( 39 ) [J]. 201533(6):670-672. [11] BanksC NLeinPJ.Areviewofexperimentalevidencelink- ingneurotoxicorganophosphoruscompoundsandinflamma- tion[j].neurotoxicology201233(3):575-584. [13] MiyatakeTTringlerBLiu Wetal.B7-H4(DD-O110)is overexpressedinhighriskuterineendometrioidadenocarcino- masandinversely correlated with tumor T-celinfiltrati- on[j].gynecoloncol2007106(1):119-127. [14] LuBChenLLiuLetal.T-cel-mediatedtumorimmunesur- 49 veilanceandexpressionofb7co-inhibitorymoleculesincanc- ersoftheuppergastrointestinaltract[j].immunolres2011 50(2-3):269-275. [15] Dufy MJBonfrerJMKulpaJetal.CA125inovariancanc- er:europeangroupontumormarkersguidelinesforclinical use[j].intjgynecolcancer200515(5):679-691. [16] SimonIZhuoSCorralLetal.B7-H4isanovelmembrane- boundproteinandacandidateserumandtissuebiomarkerfor ovariancancer[j].cancerres200666(3):1570-1575. [17] SimonIKatsarosDRigaultdelaLongraisIetal.B7-H4is over-expressedinearly-stageovariancancerandisindepend- entofca125expression[j].gynecoloncol2007106:334-341. ( : )